Jason Tardio
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jason Tardio
Jason Tardio is recorded as COO at Immunic, Inc. (IMUX). Earlier roles on record: COO at Ovid Therapeutics Inc. (OVID) until July 11, 2024. Immunic, Inc. reported in an 8-K filed July 9, 2024 that Jason Tardio was appointed Chief Operating Officer and President, effective July 12, 2024. Ovid Therapeutics Inc. reported in an 8-K filed June 28, 2024 that Jason Tardio was terminated as Chief Operating Officer, effective July 11, 2024. The proxy statement of Immunic, Inc. reports total compensation of $1,030,219 for Jason Tardio in fiscal 2024, including a base salary of $250,000. Disclosed compensation is on record for 2 fiscal years. Jason Tardio has spoken on 1 earnings call across 1 company, most recently for Immunic, Inc. on November 7, 2024.
“On July 9, 2024, Immunic, Inc. (the "Company") announced the appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.”
“Jason Tardio will cease serving as the Company’s Chief Operating Officer”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
Ovid Therapeutics Inc. (OVID)
Proxy statement
Start not stated–2021-04-30
Last confirmed by a filing; no departure on record
-
Start not stated–2024-07-11
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Immunic, Inc.
Other people whose current roles at this company are on record from its filings.
- Dr. Daniel Vitt CEO
- Duane D. Nash CEO
- Duane Nash CEO
- Erik Lundgren CEO, Board Member
- Russell J. Cox CEO
- Michael W. Bonney Chairman
- Simona Skerjanec Chairman, Board Member
- Glenn Whaley CFO
- Inderpal Singh General Counsel
- Barclay Phillips Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Immunic, Inc. (IMUX) | COO | $250,000 | $1,030,219 |
| 2022 | Ovid Therapeutics Inc. (OVID) | Chief Operating Officer | $457,600 | $1,233,850 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.